Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade

Now could be a great time to scoop up three stocks trading way below their previous peaks.

BEP : 26.23 (-0.30%)
RPRX : 28.21 (-0.11%)
BMY : 49.74 (+0.51%)
Got $200? 2 Healthcare Stocks to Buy and Hold Forever

These two stocks have had their issues in recent years, but both look like reliable long-term bets.

BMY : 49.74 (+0.51%)
GILD : 83.89 (+1.01%)
Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?

Bristol Myers Squibb Company BMY is experiencing a good run of late after touching a 52-week low of $39.35 on July 5. This short rally has given anxious investors a ray of hope. The biotech giant has been...

BMY : 49.74 (+0.51%)
PFE : 29.75 (-0.27%)
MRK : 118.64 (+0.30%)
Is Bristol-Myers Squibb Stock Underperforming the S&P 500?

Bristol-Myers Squibb has underperformed the S&P 500 over the past year, and analysts are cautious about the stock’s prospects.

BMY : 49.74 (+0.51%)
$SPX : 5,618.26 (-0.29%)
ABBV : 192.94 (-0.26%)
IPO Alert: Bristol-Myers-Backed Pharma Stock Could Gain Traction

Zenas is a Bristol Meyers Squibb-backed pharma company that is about to go public. Its treatment provides solid differentiation that could rival competitors.

NDAQ : 72.90 (+0.28%)
AMGN : 332.92 (+0.04%)
BMY : 49.74 (+0.51%)
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100

These dividend payers could more than double their payouts in the decade ahead.

PFE : 29.75 (-0.27%)
BMY : 49.74 (+0.51%)
RPRX : 28.21 (-0.11%)
Implied Volatility Surging for Bristol-Myers (BMY) Stock Options

Investors in Bristol-Myers Squibb Company BMY need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 20, 2024 $70 Put had some of the highest implied...

BMY : 49.74 (+0.51%)
2 Standout Biotech Stocks With 32% to 63% Upside

A strong pipeline of products could potentially transform these companies, but there are risks.

RNA : 44.63 (+5.78%)
$SPX : 5,618.26 (-0.29%)
BMY : 49.74 (+0.51%)
VRNA : 29.23 (+0.14%)
Is AbbVie Stock Outperforming the Nasdaq?

AbbVie has recently outperformed the Nasdaq, and Wall Street analysts are moderately optimistic about the stock’s prospects.

ABBV : 192.94 (-0.26%)
BMY : 49.74 (+0.51%)
$NASX : 17,573.30 (-0.31%)
CERE : 44.96 (+0.74%)
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High

Rebounding growth could make shares of this leading drugmaker a big winner.

BMY : 49.74 (+0.51%)

Barchart Exclusives

3 Top Dividend Stocks to Buy This September
After today's jumbo rate cut from the Fed, here are three dividend stocks to bolster your portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar